The present invention relates to a compound exhibiting STAT3 inhibitory activity, or a pharmaceutically acceptable salt, solvate or hydrate of the same, and pharmaceutical uses of these. The compounds of the present invention efficiently inhibit the abnormal activity of STAT3 associated with various diseases and thus can be usefully utilized for the prevention and treatment of various STAT3-related diseases associated with cancer, autoimmune diseases, inflammatory diseases and the like.

The invention relates to a compound of formula I, ##STR00001##
an N-oxide or an agriculturally suitable salt thereof, wherein the variables are as defined in the specification, and their use as herbicides.

The invention relates to a compound of formula I, ##STR00001##
an N-oxide or an agriculturally suitable salt thereof, wherein the variables are as defined in the specification, and their use as herbicides.

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.

A compound represented by Formula (I) [wherein, X.sup.1 represents an oxygen atom or the like; X.sup.2 represents an oxygen atom; X.sup.3 represents NH; X.sup.4 represents a hydrogen atom or the like; R.sup.1 represents C(R.sup.11)(R.sup.12) or the like; R.sup.11 and R.sup.12 are the same or different and each represents a hydrogen atom or the like; R.sup.2 represents an optionally substituted C.sup.6-C.sup.14 aromatic hydrocarbon group or the like; R.sup.3 represents an optionally substituted C.sup.6-C.sup.14 aromatic hydrocarbon group or the like; R.sup.4 represents a hydrogen atom or the like] or a salt thereof.

The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient.

A compound represented by Formula (I) [wherein, X.sup.1 represents an oxygen atom or the like; X.sup.2 represents an oxygen atom; X.sup.3 represents NH; X.sup.4 represents a hydrogen atom or the like; R.sup.1 represents C(R.sup.11)(R.sup.12) or the like; R.sup.11 and R.sup.12 are the same or different and each represents a hydrogen atom or the like; R.sup.2 represents an optionally substituted C.sup.6-C.sup.14 aromatic hydrocarbon group or the like; R.sup.3 represents an optionally substituted C.sup.6-C.sup.14 aromatic hydrocarbon group or the like; R.sup.4 represents a hydrogen atom or the like] or a salt thereof.

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

The present invention features compounds useful in the treatment of neurological disorders. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders.

The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R.sup.1, R.sup.2, R.sup.3, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, an protein misfolding disorders.

##STR00001##